Although the outcome of patients with acute myeloid leukaemia (AML) has improved with cytarabine and anthracycline-based chemotherapy regimens in addition to advances in supportive care, relapse remains frequent and constitutes the leading cause of mortality.
A number of trials exploring the combination of GO with other chemotherapeutic regimens in relapsed AML have been published (see Table 2 ). The most notable among these results is a study by Chevallier et al. that reported a CR rate of 50% and CRp rate of 13%, leading to an overall response (OR) of 63% in patients treated with a combination of IV GO 9mg/m 2 over two hours on day four, cytarabine 1g/m 2 every 12 hours IV over two hours on days one to five and mitoxantrone (MIDAM) 12mg/m 2 /day IV over 30 minutes on days one to three.
11 Grade 3-4 neutropenia and thrombocytopenia occurred in all patients and 55% patients had documented bacterial sepsis. Grade 3-4 hyperbilirubinaemia was observed in 16% patients and SOS in 3%.
Whereas single-agent therapy with GO appears to have limited activity in relapsed/refractory AML, combinations with chemotherapy are more promising and are being actively investigated. Caution should be exercised when GO is used with other hepatotoxic agents and within three to four months of SCT to avoid the development of SOS. Reduction of doses (3-6mg/m 2 ) in combination therapies has proved safer.
FMS-like Tyrosine Kinase Inhibitors
Mutations of the FMS-like tyrosine kinase (FLT3) gene cause autophosporylation of the FLT3 receptor tyrosine kinase, resulting in cell proliferation and inhibition of apoptosis. In particular, internal tandem duplications (ITD) of FLT3 confer an adverse prognosis and are seen in 25-35% of patients with predominantly diploid AML. Of the >20 molecules with inhibitory activity against FLT3, 12 the most widely studied agents in AML include midostaurin (PKC412), sorafenib (BAY43-9006), sunitinib (SU11248), lestaurtinib (CEP701) and tandutinib (MLN518) (see Table 3 ).
A phase I study testing the efficacy of sorafenib in 21 patients with relapsed/refractory AML reported a >50% reduction of the peripheral blast count in 11 patients. 16 Lestaurtinib was evaluated in a phase I-II clinical trial of 14 patients with relapsed/refractory AML. Clinical trials combining these agents have not yet been carried out.
Epigenetic Therapy
In contrast to altering the sequence of base pairs in genes, epigenetic Haematological Malignancies reported the results of a phase I-II clinical study combining decitabine (15mg/m 2 IV daily for 10 days) with valproic acid (50mg/kg daily).
27
Forty-four patients had relapsed AML. The CR rate of these patients was 14%. Another study using a combination of azacitidine (75mg/m 2 IV daily), valproic acid (50mg/kg orally daily) and all-trans retinoic acid (45mg/m 2 orally) in 53 patients (of whom 20 had relapsed AML)
showed a CR of 33% (5% in relapsed patients). 
Other Investigational Agents
Many other agents are being tested in clinical trials including farnesyltransferase inhibitors (e.g. tipifarnib), 38 bcl-2 antagonists (e.g. oblimersen), aurora kinase inhibitors (ZM447439 and VX-680), kinesin spindle protein (KSP) inhibitors (ARRY520 and AZD4788), X-linked inhibitor of apoptosis protein antisense oligonucleotide Clinical Management of Relapsed/Refractory Acute Myeloid Leukaemia
, MEK pathway inhibitors and mTOR inhibitors (temsirolimus and everolimus).
Stem Cell Transplantation
Currently, allogeneic SCT remains the only potentially curative option for patients with relapsed/refractory AML. However, patient selection bias, cross-over from chemotherapy to SCT arms, pre-treatment prognostic factors and treatment-associated morbidity and mortality make it difficult to interpret data comparing SCT with consolidation chemotherapy. Nevertheless, current data support the use of SCT in patients with primary refractory and relapsed AML.
In patients with refractory AML, outcome following allogeneic SCT is better in patients who have no peripheral blasts and <30% blasts in bone marrow prior to conditioning. 39 In a study of 21 patients who were refractory to induction chemotherapy, matched sibling SCT led to a cumulative disease-free survival (DFS) of 43% at 10 years. in the chemotherapy group (p = not significant). However, significantly higher LFS was observed in the transplant group versus the chemotherapy group in patients ≤30 years of age with CR duration greater than one year (41 and 17%, respectively), and in patients >30 years of age with CR duration less than one year (18 and 7%, respectively). Three-year treatment-related mortality was 56 and 7% with transplant and chemotherapy, respectively. 
Conclusion
Relapsed/refractory AML continues to be a therapeutic challenge.
Conventional therapies are unsatisfactory due to low response rates and a lack of translation of responses into long-term disease control. 
